

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re the application of:

Tomi JÄRVINEN et al.

Serial Number: 10/521,761

Group Art Unit: 1623

Filed: January 21, 2005

Examiner: Goon, Scarlett Y.

For: LIGNAN COMPLEXES

REQUEST FOR RECONSIDERATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 9, 2010

Sir:

In response to the Official Action mailed March 9, 2010, a Petition for a three month Extension of Time being submitted herewith, please reconsider this application in view of the following remarks. Claims 13-20 are pending.

The 35 U.S.C. § 103(a) rejection of claims 13-20 over U.S. U.S. Patent Publication 2002/0061854 to Ahotupa et al. (Reference A) in view of Loftsson et al., 85 J. Pharm. Sci. 1017 (1996), is traversed. The claimed inclusion complex comprises a cyclodextrin and hydroxymatairesinol (HMR), a geometric isomer or stereoisomer thereof, or an HMR ester.

The cited combination of references fails to raise a prima facie case of obviousness against the claimed inclusion complex